Immunohistochemical expression and localization of somatostatin receptors in normal prostate, high grade prostatic intraepithelial neoplasia and prostate cancer and its many faces

Journal of Biological Regulators and Homeostatic Agents

Volumn 26, Issue 2, 2012, Pages 181-192

  Mazzucchelli, R ^a   Scarpelli, M ^a   Lopez Beltran, A ^b   Cheng, L ^c   Di Primio, R ^a   Bono, A ^a   Montironi, Rodolfo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complete androgen ablation; High grade prostatic intraepithelial neoplasia; Hormone refractory prostate cancer; NE differentiation; Prostate; Prostate cancer; Somatostatin receptors

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ANDROGEN DEPRIVATION THERAPY; CANCER GRADING; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; ENDOTHELIUM CELL; FEASIBILITY STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCIDENTAL FINDING; INTERNALIZATION; MALE; NEUROENDOCRINE TUMOR; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SMOOTH MUSCLE FIBER; TUMOR DIFFERENTIATION;

ANDROGEN ANTAGONISTS; CELL DIFFERENTIATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE CELLS; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN;

EID: 84864983739     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179:77-9.
2. Balster DA, O'Dorisio MS, Summers MA, Turman MA. Segmental expression of somatostatin receptor subtypes sst(l) and sst(2) in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol 2001; 280:F457-65.
3. Casini Raggi C, Calabro A, Renzi D, et al. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa. Clin Cancer Res 2002; 8:419-27. (Pubitemid 34193959)
4. Hansson J, Bjartell A, Gadaleanu V, Dizeyi N, Abrahamsson PA. Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 2002; 53:50-9. (Pubitemid 34966863)
5. Kumar U. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis. Neuroscience 2005; 134:525-38. (Pubitemid 41111781)
6. Portela-Gomes MG, Stridsberg M, Grimelius L, Oberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morph 2000; 8:126-32. (Pubitemid 30609973)
7. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 1995; 80:2806-14.
8. Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004; 53:1180-9. (Pubitemid 38961975)
9. Zatelli MC, degli Uberti EC. Somatostatin receptors: from basic science to clinical approach-thyroid. Dig Liver Dis 2004; 36(S):86-92.
10. Epelbaum J, Dournaud P, Fodor M, Viollet C. The neurobiology of somatostatin. Crit Rev Neurobiol 1994; 8:25-44. (Pubitemid 24024904)
11. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20:157-98. (Pubitemid 29362641)
12. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 2005; 28:36-42.
13. Klisovic DD, O'Dorisio MS, Katz SE, Sall JW, Balster D, O'Dorisio TM, Craig E, Lubow M. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest Ophthalmol Vis Sci 2001; 42:2193-201. (Pubitemid 32848846)
14. Verset G, Verslype C, Reynaert H, et al. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer 2007; 97:582-8. (Pubitemid 47339881)
15. Mazzucchelli R, Morichetti D, Santinelli A, Scarpelli M, Bono AV, Lopez-Beltran A, Cheng L, Montironi R. Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. Cell Oncol (Dordr) 2011; 34:235-43.
16. Mazzucchelli R, Morichetti D, Scarpelli M, Bono AV, Lopez-Beltran A, Cheng L, Kirkali Z, Montironi R. Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma. Asian J Androl 2011; 13:242-7.
17. Montironi R, Cheng L, Mazzucchelli R, et al. Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction. Cell Oncol 2008; 30:473-82.
18. Morichetti D, Mazzucchelli R, Santinelli A, Stramazzotti D, Lopez-Beltran A, Scarpelli M, Bono AV, Cheng L, Montironi R. Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation. Int J Immunopathol Pharmacol 2010; 23:511-22.
19. Morichetti D, Mazzucchelli R, Stramazzotti D, Santinelli A, Lopez-Beltran A, Scarpelli M, Bono AV, Cheng L, Montironi R. Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. BJU Int 2010; 106:1072-80.
20. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sstl-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28:836-46. (Pubitemid 32662546)
21. Hornick CA, Anthony CT, Hughey S, Gebhardt BM, Espenan GD, Woltering EA. Progressive nuclear translocation of somatostatin analogs. J Nucl Med 2000; 41:1256-63. (Pubitemid 30464012)
22. Le Romancer M, Reyl-Desmars F, Cherifi Y, Pigeon C, Bottari S, Meyer O, Lewin MJ. The 86-kDa subunit of autoantigen Ku is a somatostatin receptor regulating protein phosphatase-2A activity. J Biol Chem 1994; 269:17464-8. (Pubitemid 24218023)
23. Barbisan F, Mazzucchelli R, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montorsi F, Montironi R. Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. Eur Urol 2009; 56:105-12.
24. Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer. Int J Immunopathol Pharmacol 2009; 22:755-62.
25. Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, Lòpez Beltran A. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected incystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 2006; 37:1137-44. (Pubitemid 44286977)
26. Montironi R, Mazzucchelli R, Santinelli A, Scarpelli M, Lopez-Beltran A, Bostwick DG. Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens. Hum Pathol 2005; 36:646-54. (Pubitemid 40922571)
27. Santinelli A, Mazzucchelli R, Barbisan F, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer. Am J Clin Pathol 2007; 128:657-66.
28. Dizeyi N, Konrad L, Bjartell A, Wu H, Gadaleanu V, Hansson J, Helboe L, Abrahamsson PA. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 2002; 7:91-8.
29. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71:1098-109. (Pubitemid 23049638)
30. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998; 160:1220-9. (Pubitemid 29480485)
31. Fu W, Madan E, Yee M, Zhang H. Progress of molecular targeted therapies for prostate cancers. Biochim Biophys Acta 2011; 1825:140-52.
32. Sciarra A, Innocenzi M, Ravaziol M, Minisola F, Alfarone A, Cattarino S, Monti G, Gentile V, Di Silverio F. Neuroendocrine target therapies for prostate cancer. Urologia 2011; 78:137-41.
33. Song HZ, Chen LB. Targeted therapies for hormone-refractory prostate cancer. Zhonghua Nan Ke Xue 2010; 16:1108-12
34. Curtis SB, Hewitt J, Yakubovitz S, Anzarut A, Hsiang YN, Buchan AM. Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol 2000; 278:H1815-22. (Pubitemid 30439192)
35. Badway AC, West FM, Tente SM, Blake AD. Somatostatin regulates intracellular signaling in human carotid endothelial cells. Biochem Biophys Res Commun 2004; 319:1222-7. (Pubitemid 38759541)
36. Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 1997; 70:471-9. (Pubitemid 28515732)
37. Reubi JC, Schaer JC, Laissue JA, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 1996; 45:39-41.
38. Cariaga-Martinez AE, Lorenzati MA, Riera MA, et al. Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression. Adv Urol (Epub 2009).
39. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 2000; 85:2564-71. (Pubitemid 32269216)
40. Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007; 20:1172-82. (Pubitemid 47609066)
41. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTRl, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994; 54:3455-9. (Pubitemid 24225966)